Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) Stock Information | RedChip

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)


$9.6150
+0.1650 ( +6.60% ) 589.3K

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Market Data


Open


$9.6150

Previous close


$9.4500

Volume


589.3K

Market cap


$646.17M

Day range


$8.8210 - $9.9450

52 week range


$6.0650 - $19.7100

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Nov 21, 2023
8-k 8K-related 13 Nov 09, 2023
10-q Quarterly Reports 63 Nov 09, 2023
4 Insider transactions 1 Nov 08, 2023

Latest News